---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000163"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:32:00.907076+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs

## Summary
- Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).
- $300M upfront; eligible for up to $1.35B milestones plus royalties.
- Preliminary cash: ~$0.9B actual, $1.2B pro forma including $300M upfront.
- First subject enrollment in BEAM-101 Phase 1/2 trial for sickle cell disease expected H2 2022.
- BEAM-301 (GSDIa) named fourth dev candidate; IND-enabling studies planned in 2022.

## SEC filing metadata
- accession: 0000950170-22-000163
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/0000950170-22-000163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/beam-20220109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000163
- JSON: https://secwatch.observer/filing/0000950170-22-000163.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.